Second Vimizim manufacturing site ready mid-2017, BioMarin

By Dan Stanton contact

- Last updated on GMT

BioMarin bought the Shanbally, Cork facility off Pfizer in 2011. Image: Google Streetview
BioMarin bought the Shanbally, Cork facility off Pfizer in 2011. Image: Google Streetview

Related tags: Manufacturing

BioMarin expects commercial production of its recently approved orphan drug Vimizim (elosulfase alfa) to begin at a secondary facility in Ireland – acquired from Pfizer – mid-2017.

In 2011​, drugmaker BioMarin announced it was buying Pfizer’s Shanbally biologics facility in Cork, Ireland, for $48.5m (€43m) in order to manufacture its then Phase III candidate N-acetylgalactosamine-6-sulfatase (GALNS) enzyme replacement therapy.

The product, since approved in the US​ and EU in 2014 to treat the rare congenital enzyme disorder Morquio A syndrome, is currently manufactured at the firm’s Novato, California facility and headquarters, but plans to meet commercial demand through the opening up of the secondary Shanbally site are “proceeding very well,”​ according to management.

“We are going through the process qualification manufacturing campaign now that started in the beginning of January,”​ said Robert Baffi, EVP of Technical Operations during a call discussing Q4 2015 results yesterday.

“The campaign will end in the June timeframe. We'll then have to write up the documentation and submit it. We'll probably have inspections in the first quarter of 2017 and are anticipating approval in the major regions - US and Europe - by mid-2017.”

He added Californian supplies of the product – which costs patients $380,000 for a year’s supply​ – will be “more than adequate”​ to bridge the gap until then, and then BioMarin “will be able to produce product at two different sites for Vimizim, meeting all the commercial demands as required.”

Completing validation and gaining approval at the site will contribute heavily to the firm’s expected $150-175m capital expenditure for the upcoming year, management said.

For 2015, total sales were $890m, up 18.8% year-on-year, driven by the continued global launch of Vimizim. The product itself contributed $228m to the results.

Vimizim Master Cell Bank

At the time of EU approval, the drug’s active substance was being manufactured at Novato with fill/finish – in Europe at least – being conducted by CDMO Vetter in Germany, according to the European Medicine Agency (EMA) assessment report​.

The report also described the manufacturing process using BioMarin’s cell banking system derived from a CHO-K1 cell line:

“Following transfection in the host cell line, a stable pool was generated by selection and the pool was limited-dilution cloned for single cell clones producing elosulfase alfa.

“One clone was selected from the stable clones based upon titer and viability, and was selected to use in creation of the master cell bank (MCB). The resistance marker was removed from the culture process prior to preparation of the development bank, and was not utilised during generation of the MCB.”

It added the product is purified in a sequence of chromatography, viral inactivation and filtration, and ultrafiltration/diafiltration steps.

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Related suppliers

Follow us


View more